ABSTRACT
Severe Acute Respiratory Syndrome Corona Virus-2 is the causative factor of Coronavirus Disease 2019. Early in the pandemic, mediastinal lymphadenopathy was not considered to be a significant radiologic finding of the SARS-COV-2 disease. Nevertheless, most recent studies associate mediastinal lymphadenopathy with more severe COVID-19 disease and poorer patient outcomes.
Subject(s)
COVID-19/epidemiology , Lymphadenopathy/epidemiology , Mediastinal Diseases/epidemiology , SARS-CoV-2 , COVID-19/diagnosis , COVID-19/immunology , Humans , Lymphadenopathy/diagnosis , Lymphadenopathy/immunology , Mediastinal Diseases/diagnosis , Mediastinal Diseases/immunology , Mediastinum/pathology , Prevalence , SARS-CoV-2/immunologyABSTRACT
Lymphadenopathies can be part of the clinical spectrum of several primary immunodeficiencies, including diseases with immune dysregulation and autoinflammatory disorders, as the clinical expression of benign polyclonal lymphoproliferation, granulomatous disease or lymphoid malignancy. Lymphadenopathy poses a significant diagnostic dilemma when it represents the first sign of a disorder of the immune system, leading to a consequently delayed diagnosis. Additionally, the finding of lymphadenopathy in a patient with diagnosed immunodeficiency raises the question of the differential diagnosis between benign lymphoproliferation and malignancies. Lymphadenopathies are evidenced in 15-20% of the patients with common variable immunodeficiency, while in other antibody deficiencies the prevalence is lower. They are also evidenced in different combined immunodeficiency disorders, including Omenn syndrome, which presents in the first months of life. Interestingly, in the activated phosphoinositide 3-kinase delta syndrome, autoimmune lymphoproliferative syndrome, Epstein-Barr virus (EBV)-related lymphoproliferative disorders and regulatory T cell disorders, lymphadenopathy is one of the leading signs of the entire clinical picture. Among autoinflammatory diseases, the highest prevalence of lymphadenopathies is observed in patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) and hyper-immunoglobulin (Ig)D syndrome. The mechanisms underlying lymphoproliferation in the different disorders of the immune system are multiple and not completely elucidated. The advances in genetic techniques provide the opportunity of identifying new monogenic disorders, allowing genotype-phenotype correlations to be made and to provide adequate follow-up and treatment in the single diseases. In this work, we provide an overview of the most relevant immune disorders associated with lymphadenopathy, focusing on their diagnostic and prognostic implications.
Subject(s)
Common Variable Immunodeficiency/immunology , Immunologic Deficiency Syndromes/immunology , Lymphadenopathy/immunology , Lymphoproliferative Disorders/immunology , Common Variable Immunodeficiency/diagnosis , Common Variable Immunodeficiency/genetics , Common Variable Immunodeficiency/pathology , Epstein-Barr Virus Infections/immunology , Genetic Predisposition to Disease/genetics , Herpesvirus 4, Human/immunology , Humans , Immunologic Deficiency Syndromes/diagnosis , Immunologic Deficiency Syndromes/genetics , Immunologic Deficiency Syndromes/pathology , Infant , Infant, Newborn , Lymphadenopathy/diagnosis , Lymphadenopathy/pathology , Lymphoproliferative Disorders/diagnosis , Lymphoproliferative Disorders/genetics , Lymphoproliferative Disorders/pathologyABSTRACT
Adult-onset immunodeficiency syndrome (AOIS) caused by anti-interferon-γ autoantibodies is an emerging disease. Affected patients present typically with systemic lymphadenopathy, fatigue, and fever. We studied 36 biopsy specimens, 31 lymph nodes, and 5 extranodal sites, of AOIS confirmed by serum autoantibody or QuantiFERON-TB Gold In-Tube assay. We describe the morphologic features and the results of ancillary studies, including special stains, immunohistochemistry, and molecular testing. The overall median age of these patients was 60.5 years (range, 41 to 83 y) with a male-to-female ratio of 20:16. All biopsy specimens showed nontuberculous mycobacterial infection, and most cases showed the following histologic features: capsular thickening with intranodal sclerosing fibrosis, irregularly distributed ill-formed granulomas or histiocytic aggregates with neutrophilic infiltration, interfollicular expansion by a polymorphic infiltrate with some Hodgkin-like cells that commonly effaces most of the nodal architecture and proliferation of high endothelial venules. In situ hybridization analysis for Epstein-Barr virus-encoded RNA showed scattered (<1%) to relatively more common (4% to 5%) positive cells in 29 of 30 (97%) tested specimens, reflecting immune dysregulation due to an interferon-γ defect. In the 31 lymph node specimens, 23 (74%) cases showed increased immunoglobulin G4-positive plasma cells (4 to 145/HPF; mean, 49.7/HPF) with focal areas of sclerosis reminiscent of immunoglobulin G4-related lymphadenopathy, 4 (13%) cases resembled, in part, nodular sclerosis Hodgkin lymphoma, and 9 (29%) cases mimicked T-cell lymphoma. Among 33 patients with available clinical follow-up, 20 (61%) showed persistent or refractory disease despite antimycobacterial therapy, and 1 patient died of the disease. We conclude that the presence of ill-defined granulomas, clusters of neutrophils adjacent to the histiocytic aggregates, and some Epstein-Barr virus-positive cells are features highly suggestive of AOIS. A high index of clinical suspicion and awareness of the morphologic features and differential diagnosis of AOIS are helpful for establishing the diagnosis.
Subject(s)
Autoantibodies/blood , Immunologic Deficiency Syndromes/immunology , Interferon-gamma/immunology , Lymph Nodes/immunology , Lymphadenopathy/immunology , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Biopsy , Diagnosis, Differential , Female , Herpesvirus 4, Human/isolation & purification , Histiocytes/immunology , Histiocytes/pathology , Humans , Immunologic Deficiency Syndromes/microbiology , Immunologic Deficiency Syndromes/pathology , Immunologic Deficiency Syndromes/virology , Lymph Nodes/microbiology , Lymph Nodes/pathology , Lymph Nodes/virology , Lymphadenopathy/microbiology , Lymphadenopathy/pathology , Lymphadenopathy/virology , Male , Middle Aged , Neutrophils/immunology , Neutrophils/pathology , Nontuberculous Mycobacteria/isolation & purification , Predictive Value of Tests , PrognosisABSTRACT
Early recognition of adult-onset immunodeficiency associated with neutralizing anti-interferon gamma autoantibodies (anti-IFNγ Abs) remains difficult, and misdiagnoses have been reported. Although febrile lymphadenopathy is among the most common initial manifestations of this disorder, no comprehensive clinicopathologic analysis of lymphadenopathy in patients with anti-IFNγ Abs has been reported. Here, we describe 26 lymph node biopsy specimens from 16 patients. All patients exhibited concurrent disseminated nontuberculous mycobacterial infections, and 31% received a tentative diagnosis of lymphoma at initial presentation. We found 3 distinct histomorphologic patterns: well-formed granuloma (46%), suppurative inflammation or loose histiocytic aggregates (31%), and lymphoproliferative disorder (LPD, 23%). The latter shared some of the features of malignant T-cell lymphoma, IgG4-related disease, and multicentric Castleman disease. Half of the specimens with LPD had monoclonal T cells, and 33.3% were indistinguishable from angioimmunoblastic T-cell lymphoma as per current diagnostic criteria. All lymphadenopathy with LPD features regressed with antibiotics without administration of cytotoxic chemotherapy or immunotherapy. The median follow-up time was 4.3 years. Our study highlights the substantial challenge of distinguishing between lymphoma and other benign lymphadenopathy in the setting of neutralizing anti-IFNγ Abs. Increased vigilance and multidisciplinary discussion among clinicians and pathologists are required to achieve the most appropriate diagnosis and management.
Subject(s)
Immunologic Deficiency Syndromes/diagnosis , Lymphadenopathy/diagnosis , Lymphoma/diagnosis , T-Lymphocytes/immunology , Adult , Aged , Anti-Bacterial Agents , Antibodies, Neutralizing , Autoantibodies/immunology , Autoantigens/immunology , Cell Proliferation , Female , Humans , Immunologic Deficiency Syndromes/immunology , Immunologic Deficiency Syndromes/pathology , Interferon-gamma/immunology , Lymph Nodes/pathology , Lymphadenopathy/immunology , Lymphadenopathy/pathology , Lymphoma/immunology , Lymphoma/pathology , Male , Middle Aged , Opportunistic Infections/immunology , Opportunistic Infections/pathologySubject(s)
Autoimmune Diseases , Autoimmune Lymphoproliferative Syndrome/diagnosis , Immunoglobulins, Intravenous/administration & dosage , Immunologic Tests/methods , Splenomegaly , Adult , Autoantibodies/blood , Autoimmune Diseases/blood , Autoimmune Diseases/diagnosis , Autoimmune Diseases/physiopathology , Autoimmune Diseases/therapy , Diagnosis, Differential , Diagnostic Errors/prevention & control , Genetic Testing/methods , Humans , Lymphadenopathy/diagnosis , Lymphadenopathy/immunology , Lymphadenopathy/physiopathology , Lymphadenopathy/therapy , Male , Medical History Taking , Splenomegaly/diagnostic imaging , Splenomegaly/etiology , Tomography, X-Ray Computed/methodsABSTRACT
Innate immune cellular effectors are actively consumed during systemic inflammation, but the systemic traffic and the mechanisms that support their replenishment remain unknown. Here, we demonstrate that acute systemic inflammation induces the emergent activation of a previously unrecognized system of rapid migration of granulocyte-macrophage progenitors and committed macrophage-dendritic progenitors, but not other progenitors or stem cells, from bone marrow (BM) to regional lymphatic capillaries. The progenitor traffic to the systemic lymphatic circulation is mediated by Ccl19/Ccr7 and is NF-κB independent, Traf6/IκB-kinase/SNAP23 activation dependent, and is responsible for the secretion of pre-stored Ccl19 by a subpopulation of CD205+/CD172a+ conventional dendritic cells type 2 and upregulation of BM myeloid progenitor Ccr7 signaling. Mature myeloid Traf6 signaling is anti-inflammatory and necessary for lymph node myeloid cell development. This report unveils the existence and the mechanistic basis of a very early direct traffic of myeloid progenitors from BM to lymphatics during inflammation.
When the body becomes infected with disease-causing pathogens, such as bacteria, the immune system activates various mechanisms which help to fight off the infection. One of the immune system's first lines of defense is to launch an inflammatory response that helps remove the pathogen and recruit other immune cells. However, this response can become overactivated, leading to severe inflammatory conditions that damage healthy cells and tissues. A second group of cells counteract this over inflammation and are different to the ones involved in the early inflammatory response. Both types of cells inflammatory and anti-inflammatory develop from committed progenitors, which, unlike stem cells, are already destined to become a certain type of cell. These committed progenitors reside in the bone marrow and then rapidly travel to secondary lymphoid organs, such as the lymph nodes, where they mature into functioning immune cells. During this journey, committed progenitors pass from the bone marrow to the lymphatic vessels that connect up the different secondary lymphoid organs, and then spread to all tissues in the body. Yet, it is not fully understood what exact route these cells take and what guides them towards these lymphatic tissues during inflammation. To investigate this, Serrano-Lopez, Hegde et al. used a combination of techniques to examine the migration of progenitor cells in mice that had been treated with lethal doses of a bacterial product that triggers inflammation. This revealed that as early as one to three hours after the onset of infection, progenitor cells were already starting to travel from the bone marrow towards lymphatic vessels. Serrano-Lopez, Hegde et al. found that a chemical released by an "alarm" immune cell already residing in secondary lymphoid organs attracted these progenitor cells towards the lymphatic tissue. Further experiments showed that the progenitor cells travelling to secondary lymphoid organs were already activated by bacterial products. They then follow the chemical released by alarm immune cells ready to respond to the immune challenge and suppress inflammation. These committed progenitors were also found in the inflamed lymph nodes of patients. These findings suggest this rapid circulation of progenitors is a mechanism of defense that contributes to the fight against severe inflammation. Altering how these cells migrate from the bone marrow to secondary lymphoid organs could provide a more effective treatment for inflammatory conditions and severe infections. However, these approaches would need to be tested further in the laboratory and in clinical trials.
Subject(s)
Bone Marrow/metabolism , Cell Movement , Granulocyte-Macrophage Progenitor Cells/metabolism , Inflammation Mediators/metabolism , Inflammation/metabolism , Lymphadenopathy/metabolism , Lymphatic System/metabolism , Myeloid Progenitor Cells/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Animals , Bone Marrow/immunology , Bone Marrow/pathology , Cell Lineage , Cells, Cultured , Child , Child, Preschool , Disease Models, Animal , Female , Granulocyte-Macrophage Progenitor Cells/immunology , Granulocyte-Macrophage Progenitor Cells/pathology , Humans , Inflammation/immunology , Inflammation/pathology , Lymphadenopathy/immunology , Lymphadenopathy/pathology , Lymphatic System/immunology , Lymphatic System/pathology , Male , Mice, Inbred C57BL , Mice, Knockout , Middle Aged , Myeloid Progenitor Cells/immunology , Myeloid Progenitor Cells/pathology , Phenotype , Signal Transduction , Time Factors , Young AdultABSTRACT
Genetic mutations that result in loss-of-function of the protein A20 result in an early-onset autoinflammatory disease-haploinsufficiency of A20 (HA20). The reported clinical presentations of HA20 include a Behcet's disease-like phenotype and a more lupus-like phenotype. We have identified a novel mutation in the gene encoding A20 in a pediatric patient with chronic lymphadenopathy, lupus-like symptoms, and progressive hypogammaglobulinemia. This case illustrates the wide range of clinical symptoms, including immunodeficiency, that can occur in patients with HA20.
Subject(s)
Agammaglobulinemia/genetics , Haploinsufficiency , Hereditary Autoinflammatory Diseases/genetics , Loss of Function Mutation , Lupus Erythematosus, Systemic/genetics , Lymphadenopathy/genetics , Tumor Necrosis Factor alpha-Induced Protein 3/genetics , Adolescent , Agammaglobulinemia/diagnosis , Agammaglobulinemia/drug therapy , Agammaglobulinemia/immunology , DNA Mutational Analysis , Diagnosis, Differential , Female , Genetic Predisposition to Disease , Glucocorticoids/therapeutic use , Hereditary Autoinflammatory Diseases/diagnosis , Hereditary Autoinflammatory Diseases/drug therapy , Hereditary Autoinflammatory Diseases/immunology , Heredity , Humans , Immunosuppressive Agents/therapeutic use , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/immunology , Lymphadenopathy/diagnosis , Lymphadenopathy/drug therapy , Lymphadenopathy/immunology , Pedigree , Phenotype , Predictive Value of Tests , Treatment OutcomeABSTRACT
Patients with autoimmune diseases (AD) have an increased risk to develop benign lymphadenopathies compared to patients without AD. The aim with this study was to determine the role of the PD-1 pathway and the number of cells harboring Epstein-Barr virus (EBV) in benign lymphadenopathies in patients with AD (cases) compared to patients without AD (controls). Pathology registries were screened to identify patients with biopsies diagnosed as benign lymphadenopathy and medical journals were reviewed for information on AD. Immunohistochemical stainings (PD-1 and PD-L1) and EBER in situ hybridization for EBV were applied on lymph node biopsies in patients with AD (n = 22) and patients without AD (n = 57). The case group was compared with the control group with Wilcoxon-signed rank, chi-square and Fischers exact test. There was a statistically significantly higher proportion of PD-1+ cells and a tendency for a lower prevalence of PD-L1+ and EBV+ cells in cases compared to controls. Apparently, patients with AD have an altered immune response as revealed in benign lymphadenopathies compared to patients without AD. If this association might be a piece of the puzzle for the increased risk of development of lymphomas in patients with AD remains to be determined.
Subject(s)
Autoimmune Diseases/immunology , Epstein-Barr Virus Infections/immunology , Lymphadenopathy/immunology , Programmed Cell Death 1 Receptor/immunology , Adolescent , Adult , Aged , B7-H1 Antigen/immunology , Child , Female , Humans , Lymph Nodes/immunology , Lymph Nodes/virology , Male , Middle Aged , Signal Transduction , Young AdultABSTRACT
This study investigated the frequency of and predictive factors for autoimmune lymphoproliferative syndrome (ALPS) in children with lymphoma, chronic immune cytopenia, and nonmalignant organomegaly. Thirty-four children with suspected ALPS (n=13, lymphoma; n=12, immune cytopenia; n=9, nonmalignant organomegaly) were included. Double-negative T-cells, lymphocyte apoptosis, and genetic findings were analyzed. Patients were stratified into two groups as proven/probable ALPS and clinically suspected patients according to the ALPS diagnostic criteria. Of the 34 patients, 18 (53%) were diagnosed with proven/probable ALPS. One patient had a mutation (c.652-2A>C) in the FAS gene. The remaining 16 (47%) patients were defined as clinically suspected patients. Predictive factors for ALPS were anemia and thrombocytopenia in patients with lymphoma, splenomegaly and lymphadenopathy in patients with immune cytopenia, and young age in patients with nonmalignant organomegaly. ALPS may not be rare in certain risk groups. Our study indicates that screening for ALPS may be useful in children having lymphoma with cytopenia at diagnosis, in those having nonmalignant organomegaly with immune cytopenia, and in those having chronic immune thrombocytopenic purpura or autoimmune hemolytic anemia with organomegaly developing during follow-up.
Subject(s)
Autoimmune Lymphoproliferative Syndrome/diagnosis , Leukopenia/diagnosis , Lymphoma/diagnosis , Thrombocytopenia/diagnosis , Adolescent , Anemia/diagnosis , Anemia/etiology , Anemia/immunology , Anemia, Hemolytic, Autoimmune/diagnosis , Anemia, Hemolytic, Autoimmune/etiology , Anemia, Hemolytic, Autoimmune/immunology , Apoptosis/immunology , Autoimmune Lymphoproliferative Syndrome/complications , Autoimmune Lymphoproliferative Syndrome/immunology , Autoimmune Lymphoproliferative Syndrome/pathology , Child , Child, Preschool , Chronic Disease , Cross-Sectional Studies , Female , Humans , Infant , Leukopenia/etiology , Leukopenia/immunology , Lymphadenopathy/diagnosis , Lymphadenopathy/etiology , Lymphadenopathy/immunology , Lymphoma/etiology , Lymphoma/immunology , Male , Mutation , Predictive Value of Tests , Purpura, Thrombocytopenic, Idiopathic/diagnosis , Purpura, Thrombocytopenic, Idiopathic/etiology , Purpura, Thrombocytopenic, Idiopathic/immunology , Splenomegaly/diagnosis , Splenomegaly/etiology , Splenomegaly/immunology , T-Lymphocytes/immunology , T-Lymphocytes/pathology , Thrombocytopenia/etiology , Thrombocytopenia/immunology , fas Receptor/geneticsABSTRACT
OBJECTIVE: To clarify relevant proteins and clinical characteristics of a phenotype of IgG4-related disease (IgG4-RD) with lymphadenopathy. METHODS: We enrolled patients newly diagnosed with IgG4-RD in our department between January 2000 and June 2018 and performed proteomic analysis to measure serum concentrations of 1305 proteins. We extracted proteins overexpressed in patients with IgG4-RD with lymphadenopathy by comparing between those with lymphadenopathy, those without lymphadenopathy and healthy controls. We further reviewed all the patients with IgG4-RD in our institution and investigated the characteristics and prognosis of the patients with IgG4-RD with lymphadenopathy. RESULTS: Eighty-five patients with IgG4-RD were enrolled, of which, 55% had lymphadenopathy. Proteomic analysis in 31 patients with IgG4-RD and 6 healthy controls revealed that eotaxin-3 was a potential serum biomarker in the patients with lymphadenopathy versus those without lymphadenopathy and healthy controls. A cohort of 85 patients with IgG4-RD demonstrated that patients with lymphadenopathy showed a significantly higher serum IgG4, IgG4:IgG ratio, IgG4-RD responder index and eosinophilia (P < 0.001 for all), irrelevant of the extent to which organ involvement developed. Patients with lymphadenopathy treated with glucocorticoid alone relapsed with significantly higher rates than those without lymphadenopathy (P = 0.03). CONCLUSION: Lymphadenopathy in IgG4-RD represents a phenotype associated with high disease activities, eosinophilia and relapsing disease. Eotaxin-3 is a novel biomarker related to IgG4-RD with lymphadenopathy.
Subject(s)
Chemokine CCL26/blood , Gene Expression Profiling/methods , Immunoglobulin G4-Related Disease , Lymphadenopathy , Biomarkers/blood , Correlation of Data , Eosinophilia/diagnosis , Eosinophilia/etiology , Female , Humans , Immunoglobulin G4-Related Disease/blood , Immunoglobulin G4-Related Disease/diagnosis , Immunoglobulin G4-Related Disease/physiopathology , Lymphadenopathy/diagnosis , Lymphadenopathy/etiology , Lymphadenopathy/immunology , Male , Middle Aged , Patient Acuity , Recurrence , Up-RegulationABSTRACT
Beclin 2 plays a critical role in metabolic regulation and obesity, but its functions in innate immune signaling and cancer development remain largely unknown. Here, we identified Beclin 2 as a critical negative regulator of inflammation and lymphoma development. Mice with homozygous ablation of BCL2-interacting protein 2 (Becn2) developed splenomegaly and lymphadenopathy and markedly increased ERK1/2 and NF-κB signaling for proinflammatory cytokine production. Beclin 2 targeted the key signaling kinases MEKK3 and TAK1 for degradation through an ATG9A-dependent, but ATG16L/Beclin 1/LC3-independent, autophagic pathway. Mechanistically, Beclin 2 recruited MEKK3 or TAK1 through ATG9A to form a complex (Beclin 2-ATG9A-MEKK3) on ATG9A+ vesicles upon ULK1 activation. Beclin 2 further interacted with STX5 and STX6 to promote the fusion of MEKK3- or TAK1-associated ATG9A+ vesicles to phagophores for subsequent degradation. Importantly, Becn2-deficient mice had a markedly increased incidence of lymphoma development, with persistent STAT3 activation. Myeloid-specific ablation of MEKK3 (Map3k3) completely rescued the phenotypes (splenomegaly, higher amounts of proinflammatory cytokines, and cancer incidence) of Becn2-deficient mice. Hence, our findings have identified an important role of Beclin 2 in the negative regulation of innate immune signaling and tumor development through an ATG9A-dependent, but ATG16L/Beclin 1/LC3-independent, autophagic pathway, thus providing a potential target for the treatment of inflammatory diseases and cancer.
Subject(s)
Carcinogenesis/genetics , Carcinogenesis/immunology , Immunity, Innate/genetics , Intracellular Signaling Peptides and Proteins/deficiency , Intracellular Signaling Peptides and Proteins/genetics , Intracellular Signaling Peptides and Proteins/physiology , Animals , Autophagy/genetics , Autophagy/immunology , Cytokines/biosynthesis , HEK293 Cells , Humans , Inflammation Mediators/metabolism , Lymphadenopathy/etiology , Lymphadenopathy/genetics , Lymphadenopathy/immunology , MAP Kinase Signaling System/immunology , Mice , Mice, Inbred C57BL , Mice, Knockout , NF-kappa B/metabolism , Signal Transduction/genetics , Signal Transduction/immunology , Splenomegaly/etiology , Splenomegaly/genetics , Splenomegaly/immunologyABSTRACT
El Parvovirus humano B19 puede presentarse con una amplia variedad de manifestaciones clínicas, con distinto compromiso y evolución según el huésped afectado. En pacientes inmunocomprometidos se asocia con cuadros hematológicos prolongados y graves. Se describen 3 casos de pacientes con antecedentes de infección por virus de la inmunodeficiencia humana (VIH) que desarrollaron infecciones agudas por Parvovirus B19 que se presentaron con síndrome febril, citopenias (anemia, plaquetopenia y disminución de reticulocitos) y esplenomegalia. En todos los casos el diagnóstico se confirmó por la serología específica. Todos recibieron tratamiento con inmunoglobulina humana (Ig) intravenosa (IV); 2 pacientes tuvieron buena respuesta clínica y mejoría de citopenias mientras que el restante falleció. La infección por Parvovirus B19 debe incluirse en el diagnóstico diferencial de los pacientes VIH positivos con fiebre y citopenias, principalmente anemia persistente y compromiso linfoganglionar con esplenomegalia
Human Parvovirus B 19 is presented as a variety of diseases with different compromise and evolution according to the affected host. In immunocompromised patients the acute infection due to Parvovirus B19 is associated with severe and prolonged hematological clinical pictures. Three cases of patients with a history of infection with human immunodeficiency virus (HIV) co-infected with Human Parvovirus B19 are presented. All of they presented with febrile syndrome, cytopenias (anemia, platelet count and reticulocyte reduction) and lymphadenopathy and splenomegaly. In all cases the diagnosis was confirmed by serology. All were treated with intravenous human immunoglobulin (IVI G; 2 patients had good clinical response and better cytopenias while the other died. We consider thinking about Parvovirus B19 infection in HIV immunocompromised hosts with haematological involvement, mainly persistent anemia and lymph node involvement with splenomegaly
Subject(s)
Humans , Adult , Middle Aged , Aged , Pancytopenia/immunology , Splenomegaly/immunology , Immunoglobulins/therapeutic use , HIV Infections/complications , Parvovirus B19, Human/immunology , Diagnosis, Differential , Lymphadenopathy/immunologyABSTRACT
Lymphadenopathy is frequently observed in immunoglobulin G4 (IgG4)-related disease in some cases, and such cases are known as IgG4-related lymphadenopathy. The ultrasonography findings associated with IgG4-related lymphadenopathy have not been described in previous reports. Herein, we describe ultrasonography findings in two cases of IgG4-related lymphadenopathy in conjunction with histopathological findings. Combined ultrasound scanning with Doppler examination accurately represented the specific histopathological features of IgG4-related lymphadenopathy.
Subject(s)
Immunoglobulin G , Lymphadenopathy/diagnostic imaging , Lymphadenopathy/immunology , Aged , Female , Humans , UltrasonographyABSTRACT
Galactose-deficient immunoglobulin A1 (Gd-IgA1) was recently identified as a critical effector molecule in the pathogenesis of IgA nephropathy (IgAN). Gd-IgA1 is produced by the mucosal immune system. IgAN is thought to develop because of the deposition of a circulating immune-complex containing Gd-IgA1 in the kidney. Multicentric Castleman's disease (MCD) is a rare non-neoplastic lymphoproliferative disorder. As an etiology model, hypercytokinemia, including increased levels of interleukin-6, is the primary pathogenesis of many MCD cases. Here, we present two cases of mesangial proliferative glomerulonephritis with MCD. According to renal biopsy findings, one was diagnosed with non-IgAN and the other with IgAN. Surprisingly, in both cases, Gd-IgA1 was produced by plasma cells in the lymph nodes, suggesting that Gd-IgA1 production alone does not cause IgAN; rather, it may be produced without induction by mucosal immunity. Our findings demonstrate the diversity of the development of IgAN and help to reconsider the onset mechanism of IgAN.
Subject(s)
Castleman Disease/immunology , Glomerulonephritis, IGA/immunology , Glomerulonephritis, Membranoproliferative/immunology , Immunoglobulin A/immunology , Plasma Cells/immunology , C-Reactive Protein/immunology , Castleman Disease/complications , Castleman Disease/pathology , Glomerulonephritis, IGA/complications , Glomerulonephritis, IGA/pathology , Glomerulonephritis, Membranoproliferative/complications , Glomerulonephritis, Membranoproliferative/pathology , Humans , Hypergammaglobulinemia/immunology , Immunity, Mucosal/immunology , Interleukin-6/immunology , Lymphadenopathy/immunology , Male , Middle AgedSubject(s)
Acute Kidney Injury/immunology , Glomerulonephritis/diagnosis , Lymphadenopathy/immunology , Neutropenia/immunology , Splenomegaly/immunology , Acute Kidney Injury/drug therapy , Acute Kidney Injury/pathology , Antigen-Antibody Complex/immunology , Biopsy , Bone Marrow/pathology , Child, Preschool , Diagnosis, Differential , Female , Glomerulonephritis/complications , Glomerulonephritis/drug therapy , Glomerulonephritis/immunology , Humans , IgA Vasculitis/diagnosis , Immunosuppressive Agents/therapeutic use , Kidney Glomerulus/immunology , Kidney Glomerulus/pathology , Kidney Glomerulus/ultrastructure , Lymphadenopathy/drug therapy , Microscopy, Electron , Neoplasms/diagnosis , Neutropenia/drug therapy , Splenomegaly/drug therapyABSTRACT
INTRODUCTION: In southern European countries, multicentric lymphoma and leishmaniosis are the main differential diagnoses in dogs presented with generalized lymphadenomegaly. The cytological examination is in some cases inconclusive and polymerase chain reaction (PCR) for antigen receptor rearrangement (PARR) has become a common method to confirm or rule out a lymphoproliferative neoplasia. According to the literature, leishmaniosis may lead to clonal arrangements and therefore to a false diagnosis of lymphoma, but this assumption is made from a single leishmania infected dog. Therefore, the objective of this study was to prospectively evaluate results from PARR in dogs with lymphadenomegaly due to clinical leishmaniosis at the moment of diagnosis. MATERIALS AND METHODS: 31 dogs with a diagnosis of leishmaniosis based on the LeishVet guidelines were included in the study. Samples from enlarged lymph nodes were taken for cytological examination, clonality testing and Leishmania infantum PCR. RESULTS: All 31 dogs had medium to high positive antibody titers against Leishmania spp. and 30/31 had a positive Leishmania PCR from the lymph node. A polyclonal arrangement for B cells (immunoglobulin heavy chain gene) and T cells (T-cell receptor gamma chain gene) antigen receptors was found in 28/31 dogs. Two out of 31 dogs showed a monoclonal arrangement for Ig with high (1:2) and low (1:7) polyclonal background respectively; and one of the 31 dogs showed a monoclonal arrangement for T cell receptor with low (1:3) polyclonal background. CONCLUSION: Infections with Leishmania infantum resulted in clonal rearrangement, and therefore in a possible false diagnosis of lymphoma, in 3 out of 31 dogs (9.7%). Although, PARR is a useful method to differentiate lymphoma from reactive lymphoid hyperplasia in dogs with leishmaniosis, mono-/biclonal results should be interpreted carefully, especially in the presence of any degree of polyclonal background, and together with other clinicopathological findings.
Subject(s)
Clonal Evolution , Dog Diseases/immunology , Leishmania infantum/immunology , Leishmaniasis, Visceral/diagnosis , Lymph Nodes/metabolism , Lymphadenopathy/diagnosis , Animals , Clonal Evolution/genetics , Clonal Evolution/immunology , Diagnosis, Differential , Dog Diseases/diagnosis , Dog Diseases/genetics , Dog Diseases/pathology , Dogs , Female , Gene Rearrangement, B-Lymphocyte , Gene Rearrangement, T-Lymphocyte , Genetic Testing/methods , Genetic Testing/veterinary , Leishmania infantum/genetics , Leishmaniasis, Visceral/genetics , Leishmaniasis, Visceral/immunology , Leishmaniasis, Visceral/pathology , Lymph Nodes/immunology , Lymphadenopathy/genetics , Lymphadenopathy/immunology , Lymphadenopathy/parasitology , Lymphoma/diagnosis , Lymphoma/genetics , Lymphoma/veterinary , Male , Polymerase Chain Reaction/methods , Polymerase Chain Reaction/veterinary , Prospective Studies , Splenomegaly/diagnosis , Splenomegaly/veterinarySubject(s)
Bronchial Fistula/microbiology , Fistula/microbiology , Lymphadenopathy/microbiology , Tuberculosis, Pulmonary/complications , Aged , Bronchial Fistula/immunology , Fistula/immunology , Humans , Immunocompetence , Lymphadenopathy/immunology , Male , Mycobacterium tuberculosis , Tuberculosis, Pulmonary/immunology , Tuberculosis, Pulmonary/microbiologyABSTRACT
BACKGROUND: It can be difficult to distinguish between IgG4-related lymphadenopathy and multicentric Castleman's disease (MCD) because these conditions cannot be differentially diagnosed using immunohistochemical staining alone. In this study, we analyzed the clinical features of IgG4-related lymphadenopathy and MCD patients. METHODS: We retrospectively analyzed 27 patients with MCD, including 20 with plasma cell-type (PC-type) and 7 with hyaline vascular (HV) features (mixed-type). An additional 15 patients with IgG4-related lymphadenopathy were enrolled. Clinical data and immune pathological characteristics, including serum interleukin-6 (IL-6) levels, lymph node lesion biopsies, IgG4+/IgG+ expression, and 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) images, were collected. RESULTS: The serum levels of C-reactive protein (CRP), IgA, and IL-6 were significantly elevated in the PC/mixedtype group compared with the IgG4-related lymphadenopathy group (p < 0.05). By contrast, the mean age, eosinophilia, globulin, and serum levels of IgG and IgG4 were significantly higher in the IgG4-RD lymphadenopathy group (all p < 0.05). Thirty percent of patients with IgG4-RD lymphadenopathy had elevated IL-6 levels, and 50% with MCD had elevated serum IgG4 levels. Immunohistochemical studies demonstrated the presence of numerous IgG4+ plasma cells, which accounted for > 40% of IgG4/IgG+ cells in 7 of 27 cases in the PC/mixed-type group. We first found that the mean maximum standard uptake value (SUVmax) was strongly associated with albumin and IL-6 in the IgG4-RD lymphadenopathy group, but not in the MCD group. The number of involved organs, but not the standard uptake value (SUV), helped to distinguish between the two diseases. Most PC/mixed-type group patients responded poorly to glucocorticoids when administered alone or in combination with immunosuppressant drugs. CONCLUSIONS: MCD cannot be differentiated from IgG4-related lymphadenopathy using histology alone. Systematic comparative analysis; clinical and laboratory analyses, especially 18F-FDG-PET/CT; and responses to drug treatment are therefore important parameters for distinguishing between these two diseases.
Subject(s)
Castleman Disease/blood , Immunoglobulin G/blood , Interleukin-6/blood , Lymphadenopathy/blood , Adult , Aged , C-Reactive Protein/analysis , Castleman Disease/diagnostic imaging , Castleman Disease/immunology , Diagnosis, Differential , Humans , Immunoglobulin G/immunology , Immunologic Tests/methods , Lymphadenopathy/diagnostic imaging , Lymphadenopathy/immunology , Middle Aged , Positron Emission Tomography Computed Tomography/methods , Retrospective Studies , Sensitivity and Specificity , Tomography, X-Ray Computed/methodsABSTRACT
Ga-DOTATATE PET/CT was performed in a 60-year-old man to detect culprit tumor responsible for tumor-induced osteomalacia (TIO). The images revealed multiple foci of abnormal activity in soft tissue lesion, which were not typical of tumor causing TIO in Ga-DOTATATE PET/CT. Considering other neoplastic processes, FDG PET/CT were subsequently performed, which showed all same lesions, although the lesions with highest activity were different between the scans. Pathological examination demonstrated that the patient experienced TIO caused by 1 lesion, but other lesions were due to IgG4-related lymphadenopathy.